Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
Do people living with HIV experience greater age advancement than their HIV-negative counterparts?
Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trials
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa
Kidney Diseases Associated with Human Immunodeficiency Virus Infection
A Randomized, Controlled Trial of a Behavioral Weight Loss Program for HIV-Infected Patients
CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study
Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection
Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection
Antiretroviral therapy for the prevention of HIV-1 transmission
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy
Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy
Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals
Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy
CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection
Ongoing HIV Replication Replenishes Viral Reservoirs During Therapy
Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men
Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy
Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial
Published by François RAFFI
Updated: 15 January, 2015
This publication is a follow-up of the Partners PrEP study whose results have been presented showing that daily oral tenofovir disoproxil fumarate or emtricitabine plus tenofovir disoproxil fumarate as PrEP in African heterosexual men and women at high risk of HIV acquisition because they had an HIV infected sexual partner was highly effective (respective efficacy of 67% and 75% versus placebo) (Baeten JM, et al. New England Journal of Medicine, 2012; 367:399-410 ). After this interim review, the placebo group was discontinued and the active groups were continued, and participants initially randomized to placebo were offered rerandomization in 1:1 ratio to TDF or FTC/TDF as PrEP. Of the 4,410 couples followed, 52 incident HIV-1 infections occurred, 31 in individuals assigned to TDF (incidence 0.71 cases per 100 person-years) and 21 in those assigned FTC/TDF (0.48 cases per 100 person-years). HIV-1 prevention efficacy with FTC/TDF was not significantly different from that of TDF alone (hazard ratio 0.67, 95% confidence interval 0.39-1.17; p= 0.16). Detection of tenofovir in plasma samples was associated with an 85% relative risk reduction in HIV-1 acquisition for the TDF group and 93% for the FTC/TDF group. There were no significant differences in the frequency of deaths, serious adverse events, or serum creatinine and phosphorus abnormalities between the two groups.
In conclusion, these results don't rule out the potential for a slight difference in HIV-1 protection with TDF compared with FTC/TDF, but show that once-daily oral TDF or FTC/TDF regimens both provide high protection against HIV-1 acquisition in heterosexual men and women .